Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 564 participants.

Also called NCT07335107

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 564 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07335107
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07335107. Randomized; no masking; primary purpose treatment. Start 2026-01-12 (anticipated); primary completion 2027-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion
Acronym
RESCUE-AS
Condition
Acute Ischemic Stroke
Intervention (Drug)
Intravenous Tirofiban
Intervention (Drug)
Standard Medical Therapy
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct07335107
Content hash
c393ebfa543cc608535854af93180f21323a09cedba709b7614c6ed6b6da6e02